Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Roluperidone also failed a phase 3 trial in 2020 but subsequently showed evidence that it may be able to target the negative symptoms of schizophrenia – such as apathy and social withdrawal ...